Synergy Pharmaceuticals to Present at Canaccord Genuity 33rd AnnualGrowth Conference

Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that its President and CEO, Gary S. Jacob, Ph.D., will present at the Canaccord Genuity 33rd Annual Growth Conference being held at the Intercontinental Hotel in Boston, MA. The presentation is scheduled for Wednesday, August 14th at 4:00 p.m. (EDT).

Live audio webcast of the presentation will be available under the investor relations section of Synergy’s website at www.synergypharma.com. A replay of the presentation will also be available and archived on the site for 60 days.

About Synergy Pharmaceuticals, Inc.

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy’s lead drug, plecanatide, and next generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists. Plecanatide is currently in development for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. SP-333 is in development to treat patients with inflammatory bowel disease and other GI conditions. More information is available at www.synergypharma.com